Kinoshita, Hannah
Durkee-Shock, Jessica
Jensen-Wachspress, Mariah
Kankate, Vaishnavi V.
Lang, Haili
Lazarski, Christopher A.
Keswani, Anjeni
Webber, Kathleen C.
Montgomery-Recht, Kimberly
Walkiewicz, Magdalena
Notarangelo, Luigi D.
Burbelo, Peter D.
Fuss, Ivan
Cohen, Jeffrey I.
Bollard, Catherine M.
Keller, Michael D. http://orcid.org/0000-0001-8323-3085
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01HL152161)
Jeffrey Modell Foundation
National Institutes of Health (75N91019D00024)
Article History
Received: 5 February 2021
Accepted: 15 April 2021
First Online: 13 May 2021
Declarations
:
: All patients provided written informed consent on protocols approved by the National Institutes of Health Institutional Review Board.
: See above.
: All authors concur with the submission of this manuscript, and the material submitted for publication is original research and has not been previously reported and is not under consideration for publication elsewhere.
: CMB is co-founder and on the scientific advisory boards for Catamaran Bio and Mana Therapeutics with stock and/or ownership, is on the Board of Directors for Caballeta Bio with stock options and has stock in Neximmune and Repertoire Immune Medicine.MDK is on a scientific advisory panel for Enzyvant Therapeutics. The other authors declare that there are no conflicts of interests.
Free to read: This content has been made available to all.